在开始透析前 3 个月内，比较聚乙二醇重组人促红素-β与达贝泊汀-α对慢性肾脏病患者维持血红蛋白效果的研究。

A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.

机构信息

Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

出版信息

Drugs R D. 2017 Sep;17(3):389-396. doi: 10.1007/s40268-017-0188-6.

DOI:10.1007/s40268-017-0188-6

PMID:28547536

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5629129/

Abstract

BACKGROUND AND OBJECTIVE

We compared the hemoglobin-maintaining effects between continuous erythropoietin receptor activator (CERA) and darbepoetin-α (DA) in patients with chronic kidney disease (CKD) during the 3 months before dialysis initiation.

METHODS

This study was conducted with 37 CERA-administered patients and 26 DA-administered patients who had initiated dialysis at a participating facility between January 2012 and December 2014. We investigated clinical laboratory data 3 months before and at dialysis initiation, and compared these data between the CERA and DA groups.

RESULTS

No significant differences in hemoglobin level or reticulocyte count were found between the two groups 3 months before dialysis initiation. However, at dialysis initiation, the hemoglobin level (CERA 9.82 ± 1.52 vs. DA 8.79 ± 1.07 g/dL; P = 0.003) and the reticulocyte count (CERA 5.21 ± 2.95 vs. DA 3.15 ± 1.62 × 10/μL; P = 0.004) were significantly higher in the CERA group than in the DA group. Moreover, the extent of changes in the erythropoietin resistance index during the 3 months before dialysis initiation was significantly increased in the DA group compared with the CERA group.

CONCLUSIONS

Our results suggest that CERA may be more effective than DA in maintaining hemoglobin levels in patients with CKD during 3 months before dialysis initiation.

摘要

背景和目的

我们比较了慢性肾脏病（CKD）患者在开始透析前 3 个月内，连续红细胞生成素受体激动剂（CERA）和达贝泊汀-α（DA）对维持血红蛋白的效果。

方法

本研究纳入了 2012 年 1 月至 2014 年 12 月期间在参与机构开始透析的 37 例 CERA 治疗患者和 26 例 DA 治疗患者。我们调查了开始透析前 3 个月的临床实验室数据，并比较了 CERA 和 DA 组之间的这些数据。

结果

在开始透析前 3 个月，两组的血红蛋白水平或网织红细胞计数没有显著差异。然而，在开始透析时，CERA 组的血红蛋白水平（9.82±1.52 g/dL 比 DA 组的 8.79±1.07 g/dL；P=0.003）和网织红细胞计数（5.21±2.95×10/μL 比 DA 组的 3.15±1.62×10/μL；P=0.004）均显著高于 DA 组。此外，与 CERA 组相比，DA 组在开始透析前 3 个月内红细胞生成素抵抗指数的变化程度显著增加。